| The global burden of cancer attributable to risk factors, 2010–19: a systematic analysis for the Global Burden of Disease Study 2019 KB Tran, JJ Lang, K Compton, R Xu, AR Acheson, HJ Henrikson, ... The Lancet 400 (10352), 563-591, 2022 | 434 | 2022 |
| Global, regional, and national burden of colorectal cancer and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 GBDCC Collaborators the lancet gastroenterology and hepatology, 2022 | 234 | 2022 |
| Type 1 diabetes mellitus: cellular and molecular pathophysiology at a glance B Saberzadeh-Ardestani, R Karamzadeh, M Basiri, E Hajizadeh-Saffar, ... Cell Journal (Yakhteh) 20 (3), 294, 2018 | 130 | 2018 |
| Association between survival and metastatic site in mismatch repair–deficient metastatic colorectal cancer treated with first-line pembrolizumab B Saberzadeh-Ardestani, JC Jones, JM Hubbard, RR McWilliams, ... JAMA Network Open 6 (2), e230400-e230400, 2023 | 23 | 2023 |
| Global, regional, and national burden of colorectal cancer and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019 R Sharma, M Abbasi-Kangevari, R Abd-Rabu, H Abidi, E Abu-Gharbieh, ... Lancet Gastroenterology & Hepatology 7 (7), 627-647, 2022 | 23 | 2022 |
| Association of tumor-infiltrating lymphocytes with survival depends on primary tumor sidedness in stage III colon cancers (NCCTG N0147)[Alliance] B Saberzadeh-Ardestani, NR Foster, HE Lee, Q Shi, SR Alberts, ... Annals of Oncology 33 (11), 1159-1167, 2022 | 9 | 2022 |
| A Supporting System for Management of Patients with Inflammatory Bowel Disease during COVID-19 Outbreak: Iranian Experience - Study Protocol A Anoshiravani, H Vahedi, S Nasseri-Moghaddam, H Fakheri, ... Middle East Journal of Digestive Diseases (MEJDD) 12 (4), 238-245, 2020 | 9 | 2020 |
| The global fatty liver disease Sustainable Development Goal country score for 195 countries and territories JV Lazarus, H Han, HE Mark, SA Alqahtani, JM Schattenberg, JB Soriano, ... Hepatology 78 (3), 911-928, 2023 | 8 | 2023 |
| Chemotherapy effect on daytime sleepiness and contributing factors in older adults with cancer B Saberzadeh-Ardestani, B Khosravi, J Zebardast, S Sadighi Journal of Geriatric Oncology 10 (4), 632-636, 2019 | 6 | 2019 |
| Transcriptomic signatures of MSI-high metastatic colorectal cancer predict efficacy of immune checkpoint inhibitors C Gallois, M Landi, J Taieb, M Sroussi, B Saberzadeh-Ardestani, ... Clinical Cancer Research 29 (18), 3771-3778, 2023 | 4 | 2023 |
| Outcomes of COVID-19 in patients with inflammatory bowel disease: comparison with household members and the role of IBD medications AR Sima, B Saberzadeh-Ardestani, H Vahedi, H Fakheri, ... Archives of Iranian Medicine 25 (1), 17-25, 2022 | 4 | 2022 |
| Clinical Phenotype and Disease Course of Inflammatory Bowel Disease: A Comparison Between Sporadic and Familial Cases B Saberzadeh-Ardestani, A Anushiravani, F Mansour-Ghanaei, H Fakheri, ... Inflammatory bowel diseases 28 (7), 1004-1011, 2022 | 3 | 2022 |
| Immune Marker Spatial Distribution and Clinical Outcome after PD-1 Blockade in Mismatch Repair–deficient, Advanced Colorectal Carcinomas B Saberzadeh-Ardestani, RP Graham, S McMahon, E Ahanonu, Q Shi, ... Clinical Cancer Research 29 (20), 4268-4277, 2023 | 2 | 2023 |
| Metastatic site and clinical outcome of patients with deficient mismatch repair metastatic colorectal cancer treated with an immune checkpoint inhibitor in the first-line setting B Saberzadeh-Ardestani, JC Jones, RR McWilliams, D Tougeron, ... European Journal of Cancer 196, 113433, 2024 | 1 | 2024 |
| Efficacy of pembrolizumab as first-line therapy in patients with mismatch repair–deficient metastatic colorectal cancer in relation to the metastatic site. B Saberzadeh Ardestani, JC Jones, JM Hubbard, RR McWilliams, ... Journal of Clinical Oncology 41 (4_suppl), 57-57, 2023 | 1 | 2023 |
| A Reliable Prognostic Marker for Liver Dysfunction in COVID-19 Infection ARS A Anushiravani, B Khosravi, B Saberzadeh-Ardestani, A Ghasemi, S ... Middle East Journal of Digestive Diseaes (MEJDD) 13 (3), 193-199, 2021 | 1* | 2021 |
| Spatially resolved multi-region proteomics for prediction of clinical outcome in deficient mismatch repair metastatic colorectal cancer treated with PD-1 blockade. B Saberzadeh Ardestani, Z Liu, MI Stein, W Sherman, RP Graham, ... Journal of Clinical Oncology 42 (16_suppl), 3520-3520, 2024 | | 2024 |
| Use of deep learning to evaluate tumor microenvironmental features for prediction of colon cancer recurrence FA Sinicrope, GD Nelson, B Saberzadeh-Ardestani, DI Segovia, ... Cancer Research Communications 4 (5), 1344-1350, 2024 | | 2024 |
| 92 USE OF DEEP LEARNING TO EVALUATE TUMOR MORPHOLOGICAL FEATURES FOR PREDICTION OF COLON CANCER RECURRENCE BS Ardestani, GD Nelson, DI Segovia, R Graham, C Wu, CE Hagen, ... Gastroenterology 166 (5), S-22, 2024 | | 2024 |
| The impact of prior performance information on subsequent assessment: is there evidence of retaliation in an anonymous multisource assessment system? B Saberzadeh-Ardestani, AR Sima, B Khosravi, M Young, S Mortaz Hejri Advances in Health Sciences Education 29 (2), 531-550, 2024 | | 2024 |
